Global coronavirus (CoV) disease (COVID-19) diagnoses have eclipsed 18 million, with nearly 700,000 deaths (1). Beyond optimized supportive and ventilatory care for acute respiratory distress syndrome (2), no targeted therapies have been shown to improve patient survival (3). Although numerous antiviral agents are under active investigation, only remdesivir has improved clinically meaningful outcomes, resulting in an urgent need for alternate interventions.
展开▼
